Nebula Genomics

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

Retrieved on: 
Tuesday, November 8, 2022
PCR, Medical physics, Research, Department, Gene, Dana–Farber Cancer Institute, Nature, LB-1, Radiation therapy, Company, Industry, Marketing, Dana, Dietary supplement, Environment, SEC, Cancer, Polymerase chain reaction, Acquisition, RT-PCR, COVID-19, Chromosome, CLIA, Private Securities Litigation Reform Act, Inherited disorders of trafficking, Prophase, Nasdaq, Vegetable, Linebacker, Polyphenol, Dementia, Harvard Medical School, Media relations, FDM, Nano, PIM, Toxicity, Growth, Memory, Central nervous system, Food, Trial of the century, GLOBE, Genomics, University, TK, Laboratory, OTC, Severe acute respiratory syndrome coronavirus 2, Labs, Risk, Nebula Genomics, COVID-19 testing, DNA, NASDAQ, Nano Letters, Publication, Myricetin, Inflammation, Pharmaceutical industry, Medical device, Medicinal plants, MD, Brigham

This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.

Key Points: 
  • This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.
  • ProPhase Labs is eager to explore new avenues for scientific discovery with these talented scientists as we pursue novel pathways for cancer treatment.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.
  • The company is collaborating with the Dana Farber Cancer Institute to develop LB-1 as a cancer co-therapy.

ProPhase Labs to Present at Investor Summit Group’s Q4 Conference

Retrieved on: 
Tuesday, November 8, 2022
Sheraton New York Times Square Hotel, Chromosome, CLIA, Genomics, University, TK, Laboratory, Marketing, PCR, Inherited disorders of trafficking, OTC, Prophase, Severe acute respiratory syndrome coronavirus 2, Dietary supplement, Nasdaq, Research, Nebula Genomics, Gene, COVID-19 testing, LB-1, Seventh Avenue, DNA, LB-2, FDM, PIM, Company, Food, Acquisition, RT-PCR, COVID-19, Fine chemical, Vaccine

ET

Key Points: 
  • ET
    Sheraton New York Times Square Hotel, 811 7th Avenue, W 53rd St, New York,
    The conference is completely complimentary to qualified investors.
  • Please register at Complimentary I n vestor Registr a tion
    ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase) is a growth oriented and diversified diagnostics, genomics and biotech company.
  • ProPhase Diagnostics also offers rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase Labs actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.

ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time

Retrieved on: 
Friday, November 4, 2022
Severe acute respiratory syndrome coronavirus 2, Company, Chromosome, DNA, PCR, Research, OTC, PIM, RT-PCR, FDM, COVID-19, Nasdaq, Marketing, LB-1, Nebula Genomics, LB-2, Food, Prophase, TK, Inherited disorders of trafficking, CLIA, Dietary supplement, Acquisition, Genomics, Gene, University, COVID-19 testing, Laboratory, Fine chemical, Vaccine

ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase) is a growth oriented and diversified diagnostics, genomics and biotech company.

Key Points: 
  • ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase) is a growth oriented and diversified diagnostics, genomics and biotech company.
  • The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing.
  • Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results.
  • ProPhase Diagnostics also offers rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2023

Retrieved on: 
Wednesday, November 2, 2022
Oxidative stress, Security (finance), Adjustment, Growth, Protandim, Dog, Annual report, Disclosure, Risk, EBITDA, IC, Income, Health, U.S. Securities and Exchange Commission, Dietary supplement, Optimism, Research, GLOBE, Nebula Genomics, EST, COVID-19, MST, Total, Earnings, Development, Sale, NAD, SALT, Private Securities Litigation Reform Act, Company, Table, SG, Investor relations, Skin, Hair, Daily, GAAP, Depreciation, U.S. International Development Finance Corporation, Gene, Video game, Bank, U.S

SALT LAKE CITY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first fiscal quarter ended September30, 2022.

Key Points: 
  • SALT LAKE CITY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first fiscal quarter ended September30, 2022.
  • * All comparisons are on a year over year basis and compare the first quarter of fiscal 2023 to the first quarter of fiscal 2022, unless otherwise noted.
  • For the first fiscal quarter ended September30, 2022, the Company reported revenue of $51.8 million, a 2.7% decrease over the first quarter of fiscal 2022.
  • Operating income for the first quarter of fiscal 2023 was $1.3 million compared to $4.6 million for the first quarter of fiscal 2022.

LifeVantage Declares Quarterly Dividend

Retrieved on: 
Wednesday, November 2, 2022
Oxidative stress, Security (finance), Growth, Protandim, Dog, Annual report, Risk, IC, Health, U.S. Securities and Exchange Commission, Dietary supplement, Optimism, GLOBE, Research, Nebula Genomics, COVID-19, Sale, SALT, Private Securities Litigation Reform Act, Company, Skin, Hair, Daily, Gene, Risk management

SALT LAKE CITY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced that the Companys Board of Directors has approved a quarterly cash dividend of $0.03 per share of common stock, which will be paid December 15, 2022 to all stockholders of record at the close of business on December 1, 2022.

Key Points: 
  • SALT LAKE CITY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced that the Companys Board of Directors has approved a quarterly cash dividend of $0.03 per share of common stock, which will be paid December 15, 2022 to all stockholders of record at the close of business on December 1, 2022.
  • LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health.
  • The Companys line of scientifically-validated dietary supplements includes its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements, TrueScience is the Company's line of skin, hair, bath & body, and targeted relief products.
  • LifeVantage was founded in 2003 and is headquartered in Lehi, Utah.

Blockchain in Healthcare Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 31, 2022
Health, Health Technology, Health, Genome, IBM, Blockchain, Partnership, Adoption, Confidentiality, NFT, Intelligence, Nebula Genomics, Growth, Acquisition, Vaccination, Mobile backend as a service, Technology, Data management, COVID-19, Cryptocurrency, Moderna

The "Blockchain In Healthcare Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blockchain In Healthcare Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The end-users of blockchain in healthcare include healthcare providers, pharmaceutical companies, healthcare payers, and others.
  • The regions covered in blockchain in healthcare market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
  • Care, a healthcare blockchain technology company based in Ukraine launched a decentralized care network called Global Telehealth Exchange (GTHE) using blockchain and digital currency.

Biotech Company GenoPalate Raises $5.6 Million from Investors - Investments in Personalized Nutrition and Healthy Eating Continue to Rise

Retrieved on: 
Tuesday, October 25, 2022
Nebula Genomics, Medical College of Wisconsin, DNA, Nutrient, Lactose, Caffeine, Health, Diet, Exercise, Obesity, Medical college, Metabolic syndrome, Investment, Roy Taylor (scientist), Genomics, Dietary supplement

GenoPalate, a science-based nutritional genomics company, is paving the way in the personalized nutrition industry.

Key Points: 
  • GenoPalate, a science-based nutritional genomics company, is paving the way in the personalized nutrition industry.
  • Complementing the DNA-based nutrition analysis, GenoPalate offers personalized supplements and one-on-one online nutrition programs with certified registered dietitians.
  • GenoPalate, Inc. is a science-based nutritional genomics company that is paving the way in personalized nutrition by offering revolutionary at-home DNA tests, one-on-one online nutrition programs led by registered dietitians, and personalized supplements.
  • Backed by evidence-based nutrigenomics research and DNA testing, GenoPalate empowers people to reach their optimal health through personalized nutrition.

LifeVantage to Announce First Quarter Fiscal Year 2023 Results on November 2, 2022

Retrieved on: 
Wednesday, October 19, 2022
Dietary supplement, Sale, Investor relations, Nebula Genomics, Protandim, Research, Dog, Hair, Company, SALT, Health, Skin, GLOBE, Oxidative stress, Gene

SALT LAKE CITY, Oct. 19, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its first quarter ended September 30, 2022, after the stock market closes on Wednesday, November 2, 2022.

Key Points: 
  • SALT LAKE CITY, Oct. 19, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its first quarter ended September 30, 2022, after the stock market closes on Wednesday, November 2, 2022.
  • The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.
  • Investors interested in participating in the live call can dial (855) 327-6837 from the U.S. or international callers can dial (631) 891-4304.
  • LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health.

ProPhase Labs Announces Collaboration with G42 Healthcare

Retrieved on: 
Wednesday, October 19, 2022
Dietary supplement, CLIA, NASDAQ, PCR, AI, University, International Grape Genome Program, Memorandum of understanding, Nebula Genomics, OTC, Environment, DNA, RT-PCR, Chromosome, LB-2, Gene, Solution, Population, Severe acute respiratory syndrome coronavirus 2, Artificial intelligence, Private Securities Litigation Reform Act, Company, Marketing, Prophase, PIM, GLOBE, G42, Risk, Genetics, LB-1, Health care, COVID-19 testing, Laboratory, Vaccine, Organization, Volunteering, Research, Cloud computing, Ecosystem, IROS, FDM, SEC, MOU, Genomics, Hospital, Harvard Medical School, Partnership, Nasdaq, Institution, Acquisition, Omics, Food, COVID-19, TK, Antibiotics, Pharmaceutical industry, Fine chemical

ProPhase and G42 Healthcare have also entered into an initial agreement with the goal of significantly synergizing the companies genomic sequencing capabilities to support further development and globalization of their healthcare offerings.

Key Points: 
  • ProPhase and G42 Healthcare have also entered into an initial agreement with the goal of significantly synergizing the companies genomic sequencing capabilities to support further development and globalization of their healthcare offerings.
  • G42 Healthcare is a leading health-tech company that seeks to transform the UAEs healthcare landscape with AI and advanced medical technologies.
  • G42 Healthcare is an enabler of the worlds largest and most comprehensive population genomics initiative the Emirati Genome Program, which aims to move the traditional ecosystem from sick care to preventive healthcare for UAEs citizens, making G42 Healthcare an ideal strategic relationship for ProPhase as we look to bolster our next generation sequencing capabilities and build our new state-of-the-art genomic sequencing facility, commented Ted Karkus, ProPhase Labs Chief Executive Officer.
  • As an active advisor to both ProPhase Labs and G42, I am excited that this collaboration brings together two organizations that are leaders in next-generation sequencing.

ProPhase Labs to Present at The ThinkEquity Conference

Retrieved on: 
Tuesday, October 18, 2022
Dietary supplement, Interest, Mandarin Oriental Hotel Group, CLIA, LB-1, Growth, Conference, COVID-19 testing, Laboratory, Severe acute respiratory syndrome coronavirus 2, Genomics, NASDAQ, Research, Nasdaq, PCR, Company, Marketing, Acquisition, Prophase, Board, Media relations, University, PIM, OTC, Nebula Genomics, Food, GLOBE, FDM, Director, Inherited disorders of trafficking, DNA, RT-PCR, Chromosome, LB-2, TK, COVID-19, Gene, Hotel, Vaccine

ProPhase Labs CEO and Chairman of the Board of Directors, Ted Karkus will be presenting at 11:30 AM ET on October 26th.

Key Points: 
  • ProPhase Labs CEO and Chairman of the Board of Directors, Ted Karkus will be presenting at 11:30 AM ET on October 26th.
  • The presentation will also be live-streamed at the following link:
    ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase) is a growth oriented and diversified diagnostics, genomics and biotech company.
  • ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
  • ProPhase Precision Medicine, Inc., a wholly owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA.